Cell & Gene Therapy World 2017

Phacilitate Training Course

4 bespoke, CPD accredited training courses with sector-leading experts, delivering a vital edge in either partnering strategy or product development/manufacturing.

Full Day Comparability Workshop

Christopher Bravery
9:00 – 17:00, Monday 22 January

$895

Change is inevitable and necessary both in development and over the post-approval product lifecycle. Whenever changes are made it is necessary to confirm they do not adversely impact the quality and therefore safety and efficacy of the product; this requires data beyond meeting current specifications. With any biological product this is challenging, for cell, gene and tissue products that cannot be fully characterised the challenges are greater still. Concerns about comparability undertaken during development are common issues at approval with significant comparability concerns raised during 12 of the 17 ATMP submissions to the EMA. Such questions often delay market approval or contribute to failure to get approval. This course explains what comparability is and how to develop a successful comparability protocol.

Workshop Learning Overview:

  • What is comparability?
  • Why is meeting existing specifications not comparability?
  • How do I apply the principles of comparability to highly variable products?
  • Case studies: Common mistakes with comparability and their consequences.
  • Interactive exercise: Spot the weaknesses and propose improvements to a worked comparability study
     

Register

Half Day Quality-by-Design

Anthony Davies & Jerrod Denham
9:00 – 12:30, Monday 22 January
$495

Quality by Design (QbD) is a science- and risk-based approach to pharmaceutical development. Applied to manufacturing processes, it
is intended to ensure a rational and cost-effective approach to product quality. Both the EMA and FDA have systematically assessedQbD elements of regulatory filings and, especially since the FDA’s 2011 Process Validation Guidance and the ICH’s Q8 through Q11, it has become an intrinsic part of regulatory guidance.

However, understanding and adoption of the principles of QbD has
remained relatively limited in the field of cell and gene therapy. We
strongly believe that its methodologies are critical to the successful
development of ATMPs and that they should be incorporated as
early as possible into the science of manufacturing. This workshop
will both demystify the fundamentals of QbD and provide concrete
examples of its application to this field. You will leave with a crystalclear
understanding of P Diagrams, RAMM matrices, the QTPP and
many more tools which you can immediately use to improve your
products and processes.

Register


 

Half Day Intellectual Property 101

Mark Metzke & Jason Gersting
13:30 – 17:00, Monday 22 January
$495

This session is geared towards providing an overview of intellectual
property, including trademarks, design patents and utility patents,
geared especially for those new to the process. The course will include a general overview of different types of IP that a company may employ to develop a robust portfolio to build and protect their brand, as well as their contemplated commercial products. The session will emphasize utility patents (their specifications and claims), different types of applications (provisionals, nonprovisionals, continuations, divisionals, and continuations-in-part), and what patents do and do not allow patentees to do (enforcement versus the ability to practice patents). The session will cover the nuts and bolts of the patenting process from conception of an invention, to filing/claiming strategies, to prosecution, patenting, and considerations for continued filings, with an aim to touch on domestic and international strategies at a high level. Time permitting, an interactive session will be held where filing strategies
are developed for hypothetical inventive entities.

Key Benefits:

  • High level overview of different types of IP
  • Distilled overview of utility patents and the patenting process
  • Overview of patent application types including considerations on
  • when to file
  • Interactive session to reinforce the course
     

Register

Half Day Authoring the Common Technical Document

Christopher Bravery
11:15 – 15:30, Thursday 25 January
$495

The ICH Common Technical Document was developed to standardize the way information is shared with regulators, and is accepted or mandatory by agencies following ICH (e.g. EU, US, Japan, Canada etc). The CTD is used for all types of medicinal product but the purpose of each section may not always be clear for ATMP.

This workshop aims to clarify:

  • What the purpose of each section is
  • Whether the section is descriptive or data-driven
  • What sorts of data are expected
  • Tips and considerations for style, use of figures and tables, etc.
     

Register

Pricing Explained

Each course is available to book separately, or book two half day courses for $895 and save $95! Simply register for your conference pass and add your choice of courses to your basket.

  • "The event reflected the fantastic growing enthusiasm around cell and gene therapy, including small and large companies, investors and regulators. It was great to see everyone so engaged and so positive. The event really gives you the “pulse” of what is happening right now in cell and gene therapy."
    Anne-Virginie Eggimann,
    Vice President, Regulatory Science, Bluebird Bio, Inc
  • “Great program, great people, great venue.”
    Klaus Kühlcke
    Managing Director, EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.”
    Nathalie Clement
    Associate Director, Powell Gene Therapy Center, University of Florida
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • "It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives."
    Kurt Gielen
    Acquisition & Business Development Manager, BioMedical Materials, Chemelot Campus B.V.
  • “Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.”
    Steven Goodman
    Director, Strategy and Engagement, GSK

Past Attendees

  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • abl
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • adaptim
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • aldevron
  • allele biotech attending companies
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • apogenix
  • arthrogen
  • attending pharma/biotech companies
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • brainstorm
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • gcon
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • genvec
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • key biologics
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • longeveron
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • proqinase
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • takara
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • vcls
  • attending pharma/biotech companies
  • Vineti
  • Attendign Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • world care
  • attending pharma/biotech companies
  • attending pharma/biotech companies